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AbstrACt
Introduction Diabetes affects more than 425 million 
people worldwide with a lifetime risk of diabetic foot 
ulcer (DFU) of up to 25%. Management includes wound 
debridement, wound dressings, offloading, treatment of 
infection and ischaemia, optimising glycaemic control; use 
of advanced adjuvant therapies is limited by high cost and 
lack of robust evidence.
Methods and analysis A multicentre, seamless 
phase II/III, open, parallel group, multi- arm multi- stage 
randomised controlled trial in patients with a hard- to- heal 
DFU, with blinded outcome assessment. A maximum of 
447 participants will be randomised (245 participants 
in phase II and 202 participants in phase III). The phase 
II primary objective will determine the efficacy of 
treatment strategies including hydrosurgical debridement 
± decellularised dermal allograft, or the combination 
with negative pressure wound therapy, as an adjunct to 
treatment as usual (TAU), compared with TAU alone, with 
patients randomised in a 1:1:1:2 allocation. The outcome 
is achieving at least 50% reduction in index ulcer area at 4 
weeks post randomisation.
The phase III primary objective will determine whether 
one treatment strategy, continued from phase II, reduces 
time to healing of the index ulcer compared with TAU 
alone, with participants randomised in a 1:1 allocation. 
Secondary objectives will compare healing status of the 
index ulcer, infection rate, reulceration, quality of life, cost- 
effectiveness and incidence of adverse events over 52 
weeks post randomisation. Phase II and phase III primary 
endpoint analysis will be conducted using a mixed- effects 
logistic regression model and Cox proportional hazards 
regression, respectively. A within- trial economic evaluation 
will be undertaken; the primary economic analysis will be 
a cost- utility analysis presenting ICERs for each treatment 
strategy in rank order of effectiveness, with effects 
expressed as quality- adjusted life years.
The trial has predefined progression criteria for the 
selection of one treatment strategy into phase III based on 
efficacy, safety and costs at 4 weeks.
Ethics and dissemination Ethics approval has been 
granted by the National Research Ethics Service (NRES) 
Committee Yorkshire and The Humber - Bradford Leeds 
Research Ethics Committee; approved 26 April 2017; (REC 
reference: 17/YH/0055). There is planned publication of 
a monograph in National Institute for Health Research 
journals and main trial results and associated papers in 
high- impact peer- reviewed journals.
trial registration number ISRCTN64926597; registered 
on 6 June 2017
IntroduCtIon
Diabetes currently affects more than 
425 million people worldwide,1 and this is 
expected to increase to 629 million by 2045.2 
A total of 21%–30% of patients with diabetes 
develop peripheral neuropathy or lose sensa-
tion in their feet3 4 and extrapolation from 
incidence studies suggests that lifetime inci-
dence of diabetic foot ulcer (DFU) may be as 
strengths and limitations of this study
 ► The multi- arm multi- stage design will allow ear-
ly evaluation of multiple treatment strategies in a 
phase II/III design, stopping treatments which fail 
to demonstrate sufficient improvement, evaluating 
only those showing greatest efficacy in a phase III 
trial.
 ► Comparison of multiple treatment strategies to a 
shared control group, thus requiring fewer partici-
pants compared with conventional trial designs.
 ► Clear predefined progression criteria for the selec-
tion of the treatment strategy into phase III.
 ► Pragmatic in the identification of patients with hard 
to heal ulcers.
 ► The target sample size allows only one treatment 
strategy to be taken forward into phase III.
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high as 25%.5 More than 50% of DFUs become infected, 
requiring hospitalisation, and 20% of infections result 
in amputation,6 contributing approximately 80% of 
non- traumatic amputations performed in the developed 
world.7
In the UK, diabetes affects 4.5 million people8 with 
approximately 64 000 having a DFU at any one time.9 In 
2014–2015 National Health Service (NHS) England spent 
an estimated £1 billion on DFU treatment.10 This does not 
take into account the costs imposed on the public sector 
and society as a whole through working days lost, reduc-
tions in tax revenue, increases in benefit payments and 
social care resources. Furthermore, DFUs have a major 
impact on patient health- related quality of life (HRQoL), 
including impaired physical function, mental well- being 
and social interaction.11
Management of DFUs comprises provision of National 
Institute for Health and Care Excellence (NICE) recom-
mended best ‘treatment as usual’ (TAU) through multi-
disciplinary team (MDT) DFU clinics (podiatrists, 
diabetologists, vascular surgeons etc) and concomitant 
treatment strategies including: optimising glycaemic 
control, sharp non- surgical debridement, dressing appli-
cation, off- loading, treatment of infection and isch-
aemia.12 There are a number of advanced/adjuvant 
therapies but their use is limited by high unit cost and an 
absence of robust evidence.
Despite implementation of MDT care, a national audit 
of over 33 000 ulcers reports 48.3% remain unhealed at 
12 weeks.13 Of those patients with less than the median 
reduction in DFU area at 4 weeks (<53% reduction), 
only 9% went onto heal at 12 weeks,14 while those in 
the top half for healing at 4 weeks (≥53% reduction) 
had a higher probability of healing of 58% at 12 weeks. 
Delayed healing increases the probability of adverse 
sequelae including infection and amputation.6 Drivers 
of the cost of care change with the need for hospitalisa-
tion: in a recent study community nurse visits accounted 
for 65% of total costs for healed and unhealed wounds 
managed in the outpatient setting, whereas 65% of 
costs in patients having amputation were incurred in 
secondary care.15 Thus implementation of adjuvant 
therapies, which are often more costly, is more likely to 
be cost- effective in those patients identified as ‘hard to 
heal’ (failing to decrease by >50% at 4 weeks), whereas 
those DFUs reaching >50% healing at 4 weeks are likely 
to heal without the need for more expensive interven-
tions. Those DFUs reported as unhealed at 12 weeks in 
the 2019 UK National Diabetic Foot Audit13 may have 
benefited from such therapies.
Establishing efficacious adjuvant therapies for use in 
non- healing wounds is a priority for improving healing 
rates and HRQoL, and reducing the risk of morbidity 
and cost. There is a paucity of high- quality trials assessing 
adjuvant wound therapies in DFUs, and NICE guide-
line NG19 and others have highlighted the need for 
randomised controlled trials (RCTs) of negative pressure 
wound therapy (NPWT) and other adjuvant therapies.12 16 
Technological advances in three adjuvant therapies mean 
they are now available for routine clinic use.
1. NPWT is available in a small portable pump which 
doesn’t restrict patient movement.
2. Sufficient surgical debridement which changes a 
chronic wound biology to an acute wound can now be 
undertaken using hydrosurgical debridement (HD) 
under local anaesthetic in clinic, enhancing patient ex-
perience and reducing costs by avoiding additional hos-
pital visits for day- case surgery. This also allows wound 
bed preparation to a ‘graft ready state’ for advanced 
wound adjuncts, a state which cannot be achieved by 
less aggressive debridement with wound debridement 
pads such as Debrisoft. HD has been shown to be as 
effective as operating theatre surgical debridement in 
wound healing outcomes.17
3. Decellularised dermal allograft (DCD) has been used 
in the USA for treatment of DFU, with improved heal-
ing compared with standard care18 19 but cost has been 
prohibitive in the UK. A novel DCD, prepared from 
skin donated by voluntary UK deceased donors and 
recently been developed within the NHS, is approved 
by the Human Tissue Authority and is available for 
use in the UK. DCD is prepared and supplied by NHS 
Blood and Transplant (a Department of Health special 
health authority). However, the application of DCD re-
quires surgical debridement to a ‘graft ready wound 
bed’ and it is not known whether the surgical debride-
ment alone leads to improved healing in this setting.
Performing multiple RCTs to assess each intervention 
individually would be time- consuming and expensive. 
Moreover, these therapies are often used in combina-
tion. The Multiple Interventions for Diabetic Foot Ulcer 
Treatment Trial (MIDFUT) uses an efficient, informative 
and ethical, adaptive, multi- arm, multi- stage (MAMS) 
design.20 This involves early evaluation of combinations 
of the candidate interventions in a phase II/III design, 
stopping recruitment to treatment strategies which fail 
to demonstrate sufficient improvements in DFU healing, 
using an intermediate endpoint at 4 weeks post rando-
misation, and evaluating only one treatment strategy 
showing greatest efficacy in a phase III trial.
The evidence for adjuvant therapies for DFU treatment 
was reviewed in NICE guideline NG19,12 which concluded 
that the quality of trials was poor due to binary and early 
endpoints and small sample sizes. It recommended that 
future trials are sufficiently powered, with outcomes 
including time to healing, incidence and extent of ampu-
tation (major or minor), ulcer recurrence, HRQoL, 
adverse events (AEs), hospital admissions and length of 
stay. These findings were supported by a review by the 
International Working Group on the Diabetic Foot.21
In summary, quality data on the outcome of adjuvant 
therapies for DFU is rare. A 30% increase in prevalence 
of disease is anticipated by 2035, which will add to the 
already substantial costs of treating DFUs, in a time of 
global fiscal uncertainty. With international guidance 
advocating the need for robust RCTs in this area,21 and 
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technical advancements in three adjuvant therapy options 
(HD, DCD and NPWT), an RCT to compare treatment 
strategies is timely.
objectives
In phase II, the aim is to identify the most promising of 
the three treatment strategies compared with TAU using 
short- term efficacy and in phase III, to investigate the 
clinical and cost effectiveness of one treatment strategy 
from phase II compared with TAU in the treatment of 
patients with hard- to- heal DFUs.
Phase II primary objective
To determine the efficacy of the treatment strategies:
1. TAU + HD alone.
2. TAU +HD + DCD.
3. TAU +HD + NPWT+ DCD
compared with TAU alone using the short- term inter-
mediate outcome of achieving at least 50% reduction in 
index ulcer area at 4 weeks post randomisation (phase II 
primary endpoint).
Phase III primary objective
To determine whether one treatment strategy continued 
from phase II, as an adjunct to TAU, reduces time to 
healing of the index ulcer compared with TAU alone.
The primary endpoint is time to healing of the index 
ulcer from randomisation to the date the index ulcer 
is confirmed as healed at the first confirmation visit 
conducted by the blinded assessor (providing the index 
ulcer is confirmed as healed at a second clinical assess-
ment 2 weeks later).
Phase III secondary objectives
To compare one treatment strategy as an adjunct to TAU, 
continued from phase II, with TAU alone for:
 ► Healing status of the index ulcer at 12, 20 and 52 
weeks.
 ► Rate of ulcer infection in the foot of the index ulcer 
over 52 weeks post randomisation.
 ► Incidence of reulceration following healing of index 
ulcer over 52 weeks post randomisation.
 ► Quality of life using the Diabetic Foot Ulcer 
Scale—Short Form (DFS- SF) and the Five- level five- 
dimension EuroQol (EQ- 5D- 5L) over 52 weeks post 
randomisation.
 ► Incidence of AEs (including amputation, infection in 
any ulcer on the foot of the index ulcer and hospital 
admission) over 52 weeks post randomisation.
 ► Cost effectiveness over 52 weeks.
Phase III exploratory objective
To explore factors prognostic of ulcer healing.
MEthods
MIDFUT is a multicentre, seamless phase II/III, open, 
parallel group, MAMS RCT in patients with a hard- to- heal 
DFU, with blinded outcome assessment.
The MAMS trial design will allow an early evaluation 
of three candidate treatment strategies in a phase II/III 
design. Randomisation to treatment strategies that fail 
to demonstrate sufficient improvement in index ulcer 
healing at the end of phase II will be stopped. Only one 
treatment strategy showing greatest early efficacy will 
undergo clinical and cost- effectiveness assessment in 
phase III (see figure 1 for a schematic of the design).
Three treatment strategies will be compared with TAU 
in phase II. Treatment strategies for which the estimated 
proportion of responders is less than 10% higher than 
the proportion of responders on TAU (absolute differ-
ence) will be dropped at the end of phase II (response 
defined as achieving at least 50% reduction in wound 
area of the index ulcer). One treatment strategy and TAU 
will be evaluated in phase III. If more than one treatment 
strategy shows a sufficient response in phase II, then 
the decision on which treatment strategy to evaluate in 
phase III will consider information on the safety profile 
and costs of the treatment strategies up to 4 weeks post 
randomisation.
A maximum of 447 participants will be recruited, 245 
participants in phase II and at most 202 participants in 
phase III. Recruitment at centres will continue without 
interruption between phase II and phase III.
All participants from phases II and III will be followed 
up at weeks 1, 2, 4, 8, 12, 20 and 52 post randomisation 
(including those where healing of the index ulcer has 
been confirmed), or week 54 where healing of the index 
ulcer is first reported at week 52 (see figure 2).
The trial includes a 9- month internal pilot phase in 
phase II to evaluate the feasibility of recruitment and 
therefore delivery of the trial.
Moreover, a Study Within A Trial will be included to 
determine the extent of agreement in the assessment of 
healing between central blinded photography review and 
the clinical assessment of healing.
An interim analysis will be conducted after 220 partic-
ipants have reached 52 weeks post randomisation to 
re- estimate the overall loss to follow- up rate and the final 
sample size. The review will be conducted in a blinded 
manner.
recruitment/consent
The trial will be conducted in secondary care and 
community clinics that provide a MDT DFU service 
(which includes as a minimum a clinician trained in each 
trial intervention, a podiatrist, a diabetologist, a vascular 
surgeon and an orthotist).
Patients under the care of the MDT DFU outpatient 
clinics, with a current DFU, surgical debridement wound 
or minor amputation wound, will be assessed for eligi-
bility in accordance with the criteria in box 1.
Potentially eligible patients will receive a verbal expla-
nation of the study and a patient information leaflet 
(PIL) by the attending clinical/research team. Strategies 
to encourage recruitment include:
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Figure 1 Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT) design.
 ► Posters and/or leaflets in clinic waiting areas and 
other appropriate locations.
 ► Letter and PIL sent to patients with their outpatient 
appointment letter.
 ► Study included on relevant websites and research data-
bases that can be accessed by members of the public.
 ► Ethically approved tweets on Twitter.
Following information provision, patients will have 
as long as they need to consider participation and to 
discuss the study with their family and other healthcare 
professionals before consent to participate in the study is 
requested.
Assenting patients will be invited to provide informed 
consent and complete an eligibility assessment. Full 
informed consent will be obtained for all participants 
prior to the participant undergoing procedures that are 
specifically for the purposes of the study and are not part 
of TAU at the participating centre.
Witnessed consent by a representative who is indepen-
dent of the trial will be available where relevant.
Patients who provide written/witnessed verbal informed 
consent, but subsequently lose capacity will be withdrawn 
from the trial.
non-randomised patients
Participating research sites will complete a log of all 
patients presenting with a DFU and considered for the 
trial, but not recruited. Anonymised information to be 
collected includes age, sex, ethnicity, reason not eligible 
or reason declined participation.
randomisation
Following confirmation of eligibility, consent and 
completion of baseline assessments, participants will be 
randomised. In phase II, randomisation will be in a 1:1:1:2 
allocation ratio to the three treatment strategies and TAU 
group, respectively, as an approximation to Dunnett’s 
recommendation.22 In phase III, randomisation will be in 
a 1:1 allocation ratio to one treatment strategy and TAU. 
Randomisation in both phases will use a minimisation 
algorithm, incorporating a random element, via a central 
24 hours automated telephone or internet randomisation 
system, based at the Leeds Clinical Trials Research Unit 
(CTRU). The dynamic allocation method will ensure the 
groups are well balanced for:
 ► Centre.
 ► Aetiology (neuropathic or neuro- ischaemic).
 ► Index ulcer duration (<6 months, ≥6 months).
 ► Anatomical site (forefoot, midfoot/hindfoot).
 ► Presentation (DFU, surgical debridement wound, 
open minor amputation).
In addition, at the time of randomisation, 25% of partic-
ipants will be randomly selected to have photographs of 
the index ulcer taken, if it is unhealed, at weeks 12, 20 
and 52, for central blinded review.
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Figure 2 Flow diagram. TAU, treatment as usual.
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box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Aged ≥18 years.
2. Diagnosis of diabetes mellitus (according to WHO criteria).47
3. Has a chronic diabetic foot ulcer (DFU) or surgical debridement 
wound or open minor amputation and in the opinion of the attending 
clinical team is not on a healing trajectory despite usual best care 
for a minimum of 4 weeks since initial presentation at the multidis-
ciplinary team (MDT) DFU service.*
4. The index DFU has an area ≥0.8 cm2.
5. Ankle brachial index for the leg of the index ulcer ≥0.7 or non- 
compressible (measurements available in the participants notes 
taken within 3 months of randomisation can be used if no change in 
intervention or vascular events have occurred).
6. Expected to comply with the treatment strategies and follow- up 
schedule.
7. Consent to foot and wound photography.
8. Consent to participate (written/witnessed verbal informed consent).
Exclusion criteria
1. Has any current clinically infected DFU on the foot of the index ulcer 
(as per Infectious Diseases Society of America (IDSA) guidelines).48
2. Glycated haemoglobin (HbA1c)>110 mmol/mol (measurements 
available in the participants notes taken within 3 months of ran-
domisation can be used if no change in intervention or vascular 
events have occurred).
3. Estimated glomerular filtration rate (eGFR) <20 mL/min/1.73 m2 
(measurements taken within 3 months of randomisation can be 
used if no change in intervention or vascular events have occurred).
4. Index ulcer duration >2 years.
5. Planned or previous treatment with corticosteroids to an equivalent 
dose of prednisolone >10 mg per day or other immunosuppressive/
immunomodulating therapy within 4 weeks prior to randomisation.
6. Has evidence of connective tissue disorders as a cause of ulcera-
tion (eg, vasculitis or rheumatoid arthritis).
7. Has evidence of dermatological disorders as a cause of ulceration 
(eg, pyoderma gangrenosum or epidermolysis bullosa).
8. Planned or previous growth factor treatment within 4 weeks prior 
to randomisation.
9. Planned or previous revascularisation or foot surgery affecting 
healing on the foot of the index ulcer within the 4 weeks prior to 
randomisation.
10. Index ulcer base has bone or joint involvement.
11. Previously received decellularised dermal allograft (DCD) for the 
index ulcer within 4 weeks prior to randomisation.
12. Previously received negative pressure wound therapy (NPWT) for 
the index ulcer within 4 weeks prior to randomisation.
13. Previously received hydrosurgical or surgical debridement for the 
index ulcer within 4 weeks prior to randomisation.
14. Has previously been randomised to the Multiple Interventions for 
Diabetic Foot Ulcer Treatment Trial (MIDFUT) Study.
15. Unable to receive one or more of the randomised treatment strate-
gies for any reason at the discretion of the attending clinical team 
(eg, risk of excessive bleeding, serious falls risk, known allergies to 
NPWT dressings or dCELL dermis preparation components).
*Defined as failure to achieve >50% reduction in index ulcer area over a 
minimum of 4 weeks using local wound measurement policies.
blinding
Due to the nature of the treatment strategies it is not 
possible to blind participants, the clinicians or research 
team to the treatment group allocation. However, primary 
outcome assessments will be conducted by an indepen-
dent clinical assessor with no knowledge of treatment 
allocation. To mitigate risk of assessment bias the blinded 
assessor will also have no access to participant notes or 
trial case report forms. Blinding will be maintained when 
tracings and photographs at week 4, and confirmation of 
the index ulcer healing assessments, are returned to the 
CTRU (eg, through separate mail or independent cler-
ical staff).
For the phase II primary outcome and phase III 
exploratory objective, a blinded assessor at each site will 
complete an acetate tracing and take a two- dimensional 
digital photograph of the index ulcer at week 4. Measure-
ments will be obtained from the index ulcer tracing using 
‘Image J’ software23 by a member of the CTRU team who 
is independent of the research teams at recruiting sites 
and blind to treatment allocation. A photograph of the 
index ulcer will be taken as a backup in the event that 
a tracing cannot be taken or is of insufficient quality to 
determine the index ulcer outline.
For the phase III primary endpoint, all participants 
recruited to both phase II and III will also have a photo-
graph taken of the reported healed index ulcer by the 
blinded assessor within 3 days of healing being reported 
and 2 weeks later as a confirmation of healing, which will 
undergo blinded central review.
Photographs taken of healed and of unhealed 
index ulcers for randomly selected participants will be 
submitted for central blinded photography review by 
clinical members of the Trial Management Group who 
will not be aware of the participant’s identity, treatment 
group or time point at which the photograph was taken.
Interventions
All randomised treatment strategies will be applied to the 
index ulcer as a ‘once only intervention’ on the day of 
randomisation in the MDT DFU service clinic, with the 
exception of NPWT which will be applied until the 2 week 
visit. Treatment of any other ulcers will continue as per 
the treating clinician’s decision.
At baseline, randomisation and each follow- up visit all 
participants will receive TAU. At the randomisation treat-
ment visit, the participant will be randomised to receive 
the treatment strategy specific to the arm of the trial for 
the index ulcer. This will include one or more of the 
following:
Treatment as usual
Participants will receive the minimum standard care 
provided by the recruiting centre. This will be in line with 
NICE guidelines12 and is likely to include attendance at 
the MDT DFU service clinic(s) at least fortnightly until 
healing is confirmed for wound assessment, sharp non- 
surgical debridement of callous/non- viable tissue, review 
of off- loading and to optimise diabetes and wound assess-
ment as required, including community services visits, 
typically once to two times weekly. In line with NICE 
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guidelines, use of removable below- knee walking device 
or removable cast walker will be encouraged. Wound 
dressing changes will be performed between clinic visits 
according to local policies.
Hydrosurgical debridement
HD, a one- off procedure on the day of randomisation, 
applies saline at high pressure via a pump through a 
hand piece. This has an operating window located at the 
instrument’s distal tip. During operation the flow of pres-
surised saline creates a local vacuum. As the operating 
window of the handset is passed over the tissue, non- 
viable material and debris are removed. The ulcer bed 
is debrided to healthy bleeding tissue which may require 
local anaesthetic.
Negative pressure wound therapy
NPWT, applied on the day of randomisation, consists of 
a foam dressing cut to shape and applied to the wound. 
An airtight seal is established with a film dressing; this is 
then connected to a pump which applies gentle suction 
to the wound. This allows the removal of fluid from the 
wound, which is collected in a canister attached to the 
pump, which is carried by the participant at all times in 
the bag provided. Alternatively, a self- contained system 
consisting of a disposable NPWT pump attached to an 
absorbent adhesive dressing may be used. The dressing is 
usually changed at least once a week, and the NPWT will 
be applied for 2 weeks post randomisation.
Decellularised dermal allograft
DCDs are prepared from split skin grafts obtained from 
deceased human tissue donors, which are processed and 
sterilised. Processing retains the normal skin structure, 
but removes donor cells and cell remnants meaning the 
graft is not rejected and functions as a permanent tissue 
replacement. On receipt at participating sites, the graft 
will be stored between 0°C and 40°C until the expiry date 
stated on the graft label. Prior to application the graft 
is soaked in a bowl of sterile saline solution for 15 min. 
The graft is then cut to size using sterile scissors and 
applied directly to the debrided wound bed, epidermal 
side upwards. Following application, the ulcer is covered 
with a non- adherent contact layer and a secondary bolster 
dressing or NPWT (as per randomisation). In those 
DFUs allocated to DCD, the wound bed is not debrided 
for 4 months post- treatment, unless clinically indicated, 
although debridement of wound edge and surrounding 
tissue can continue as per TAU.
Assessments/data collection and follow-up
Baseline assessment
Participant demographics including date of birth, gender, 
ethnicity, NHS number and site of the index ulcer will be 
recorded.
Clinical history will be recorded including smoking 
history, duration and type of diabetes, number of ulcers 
and index ulcer characteristics, for example, first or 
recurrent ulcer, aetiology, existing wound therapies and 
Site, Ischaemia, Neuropathy, Bacterial Infection and 
Depth (SINBAD) classification.24 Initial index ulcer area 
tracing (using acetate) will also be obtained. Participants 
will be asked to complete quality of life questionnaires: 
DFS- SF and EQ- 5D- 5L.
Randomisation and application of the treatment 
strategy will take place after baseline assessments and 
questionnaires have been completed, on the same day.
Information collected post- treatment will include 
details of the treatment strategy applied to the index 
ulcer and to any other ulcers on the foot of the index 
ulcer, and expected AEs and serious AEs (SAEs). Post HD 
debridement, index ulcer area acetate tracing and photo-
graphs will be obtained.
Follow-up assessments
At a routine clinic assessment at week 1 and at weeks 2, 
4, 12, 20 and 52 post randomisation the following assess-
ments will be conducted by a member of the clinical 
research team (clinician, clinical research nurse or regis-
tered healthcare professional): healing status of the index 
ulcer, episodes of infection in the foot of the index ulcer 
(IDSA criteria), revascularisation of the index limb, index 
ulcer treatments and expected AEs or SAEs. In addition, 
at weeks 1 and 2 post randomisation, an assessment of 
compliance with NPWT and DCD (where applicable), 
and at weeks 2–52 post randomisation an assessment of 
reulceration of the index ulcer will be conducted. At week 
2 and week 4 post randomisation, an acetate tracing and 
photograph of the index ulcer post sharp non- surgical 
debridement (where clinically indicated) will be taken; at 
week 4 this is conducted by a blinded assessor (clinician, 
research nurse or registered healthcare professional).
Participant questionnaires (DFS- SF, EQ- 5D- 5L and 
healthcare resource utilisation (HRU)) will be completed 
at weeks 4, 12, 20 and 52 post randomisation; the HRU 
questionnaire will also be completed at week 8 post 
randomisation.
Healing and reulceration assessments
Healing is defined as complete closure of the ulcer: 
100% re- epithelialisation of the wound surface with the 
absence of drainage, confirmed by blinded assessment of 
index ulcer healing status at two consecutive assessments 
2 weeks apart.25
Healing of the index ulcer will be reported in one of 
the following scenarios:
 ► By the research nurse/registered healthcare profes-
sional at a research visit.
 ► During the participant’s routine appointment at the 
MDT DFU service clinic, podiatry clinic, GP practice 
nurse and/or at home by district nurses as per TAU.
 ► Participant self- reporting to the research team or 
to the attending clinical team in between routine 
appointments who will then inform the research team.
The attending clinical team will contact the research 
team to report the date the index ulcer was first noted 
as healed, who will then arrange an initial visit within 3 
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days of healing of the index ulcer first being reported 
and a 2- week follow- up visit (±3 days) with the blinded 
assessor to assess index ulcer healing status and conduct 
photography.
Reulceration is defined as recurrence of a full thickness 
break in the epithelium at the same location as the index 
ulcer.26 Reulceration of the index ulcer will be established 
either by participant self- referral to the research team, at 
a routine clinic or research appointment or by contin-
uous screening of new referrals to the MDT DFU service 
clinic where participants will be flagged to the research 
team by the attending clinical team. Reulceration of the 
index ulcer will be confirmed by a blinded assessor, within 
7 days of reulceration being reported, with reference to 
the photograph of the foot taken at the randomisation 
visit, photography undertaken and the date of reulcer-
ation of the index ulcer recorded.
sample size
The planned maximum sample size is 447 participants, 
245 participants in phase II and 202 participants in 
phase III. The apportionment of participants to phase II 
and phase III was estimated using a series of simulation 
studies.
In phase II, 49 participants per treatment strategy arm 
and 98 participants in the TAU arm will be recruited. The 
target effect size in phase II is an absolute increase of 25% 
in the proportion of participants achieving at least a 50% 
reduction in wound area by 4 weeks post randomisation, 
assuming 39% reach at least a 50% reduction by week 4 
in the TAU arm (local audit data) and 64% achieve this 
outcome in the treatment strategy arms.
An additional 101 participants will be recruited into 
each arm evaluated in phase III, corresponding to a total 
(phase II and III combined) of 150 in the remaining 
treatment strategy group and 199 in the TAU arm (total 
of 349 participants for evaluation in phase III).
The minimum clinically important effect size in phase 
III is a hazard ratio (HR) of 1.5, assuming a median time 
to healing of 21 weeks for the TAU arm (local audit data) 
and 14 weeks for the treatment strategy arms18 27–30 and 
18.0% and 7.6% unhealed at 52 weeks in the TAU and 
treatment strategy groups, respectively (assuming expo-
nential distribution for time to healing).
Several scenarios for the power of the trial have been 
considered. In all cases a 10% loss to follow- up by 4 weeks 
and 25% loss to follow- up by 52 weeks is assumed. In the 
case where there is a single effective treatment strategy 
arm, the design has 83.9% power to recommend a truly 
effective treatment strategy (ie, for it to progress from 
phase II and for a significant result found at phase III). A 
treatment strategy group that progresses to phase III and 
which is significantly better than TAU at the two- sided 
4% significance level (to control the familywise error rate 
at 5%) on the time to healing endpoint will be declared 
clinically effective.
A formal sample size review will be conducted at 52 
weeks, after 220 participants have been recruited, to 
re- estimate the proportion of participants lost to follow- up 
by 52 weeks post randomisation and the final sample size. 
The review will allow the overall loss to follow- up to be 
estimated to a minimum precision ±5.7% (corresponding 
to half width of the 95% CI), assuming a maximum loss to 
follow- up of 25%.
Progression criteria for phase III
The minimum criterion for taking treatment strategies 
forward into phase III will be defined as at least a 10% 
increase in the probability of achieving ≥50% reduction 
in index ulcer area at 4 weeks post randomisation above 
that observed for TAU, corresponding to the minimum 
clinically important difference (clinical opinion). If more 
than one treatment strategy passes this threshold at phase 
II then the selection criteria will be based on a combina-
tion of efficacy, safety profile and cost of treatment strat-
egies up to 4 weeks post randomisation. The progression 
criteria are provided in further detail in box 2.
statistical analysis
A statistical analysis plan for phase II and phase III final 
analyses will be finalised and signed off before any data 
analyses are conducted.
The complete case population will be used for the anal-
ysis of the phase II endpoint under the assumption that 
data are missing at random (MAR).31 A sensitivity analysis 
will be considered if there is differential missing endpoint 
data observed across treatment arms.
Phase III analyses will use intention to treat whereby 
participants will be analysed according to randomised 
treatment group. A per- protocol population will also be 
defined.
For phase III endpoint analyses, data from all partici-
pants recruited in phase II and phase III will be included.
Phase II primary endpoint analysis
Primary analysis
Treatment effects and 95% confidence intervals on 
response at 4 weeks will be estimated from multivariable 
mixed- effects logistic regression, including the minimi-
sation factors and treatment group as fixed effects and 
centres as random effects. Simple contrasts for each treat-
ment strategy compared with the TAU arm will be used.
Phase II secondary endpoint analysis
AEs and SAEs that are classified as expected and related 
to DFUs and trial treatment strategies, or RUSAEs will be 
summarised by treatment group.
Mean per- patient costs of treatment, healthcare use 
and total resource use, together with a measure of vari-
ance will be reported by treatment group.
Phase III primary endpoint analysis
Primary analysis
The hazard ratios for the phase III endpoint will be 
estimated using Cox proportional hazards regression 
with covariates for the minimisation factors, treatment 
arm (fixed effects) and centre (random effects) and 
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box 2 Phase II to phase III progression criteria
The progression criteria for the selection of treatment strategies into 
phase III is based on the following process:
1. Calculate the point estimate for the proportion of participants with 
≥50% ulcer area reduction at 4 weeks post randomisation in all four 
arms (phase II endpoint). Drop treatment strategy arms for which 
this proportion is less than 10% higher (on the absolute scale) than 
that of TAU. That is, if the proportion for TAU is 39% then recommend 
dropping treatment strategies for which the proportion is less than 
49%. Rank the remaining treatment strategies in order of clinical 
activity.
Note: An absolute improvement of 10% in the proportion of participants 
with ≥50% ulcer area reduction at 4 weeks post randomisation corre-
sponds to the critical cut point for the selection of treatment strategies 
based on clinical activity.
1. If more than one treatment strategy has a success rate at 4 weeks 
of at least 10% greater than TAU then summarise SAEs and rank 
order of treatment strategies in terms of their safety profile. Only AEs 
and SAEs that are classified as expected and related to DFUs or tri-
al treatment strategies, or ‘related and unexpected SAEs’ (RUSAEs) 
will be considered. Decision on whether to drop treatment strategies 
with the ‘least favourable’ safety profile will be made by the Data 
Monitoring and Ethics Committee (DMEC).
2. If more than one treatment strategy remains after stages (1) and (2) 
then summarise treatment- related costs up to 4 weeks and rank 
order of treatment strategies by ascending cost of treatment versus 
TAU. Decision on whether to drop the treatment strategies with the 
highest cost will be made by the DMEC.
3. If no treatment strategies remain, then recommend terminating re-
cruitment to the trial. If one remains, take this forward to phase III. 
If more than one treatment strategy satisfies (1) to (3), take forward 
the top performing arm defined by clinical activity (the extent of im-
provement in the proportion of participants achieving the phase II 
endpoint).
The trial will also have a futility rule to allow for stopping of the trial on 
the basis of no treatment strategy demonstrating at least 10% absolute 
improvement in the success rate of the phase II primary outcome. This 
will be non- binding to allow the DMEC to make the final recommenda-
tions to the Trial Steering Committee (TSC) on whether or not to stop 
the trial.
stratification for the phase in which the participant was 
recruited.
Phase III secondary endpoint analysis
Similar regression- based analyses will be used for other 
secondary endpoints. Cumulative incidence of healing at 
12, 20 and 52 weeks post randomisation will be obtained 
from the primary endpoint analysis model. A Poisson- 
Gamma regression model will be fitted to infection status 
over time. A Cox proportional hazards regression model 
will be fitted to time to reulceration of the index ulcer 
on those participants where healing of the index ulcer 
is confirmed. A repeated measures, random coefficients, 
linear regression model will be fitted to the DFS- SF Score 
over time.
All AEs and SAEs, including amputations and admis-
sions to hospital, will be recorded and summarised by 
treatment strategy received. Expected treatment- related 
AEs include: pain, bleeding and infection from HD; 
bleeding, infection and skin irritation/breakdown from 
NPWT; seroma and allergic reaction from DCD.
Exploratory analyses
Sensitivity analyses
For all analyses using the Cox proportional hazards 
model, the assumption of independence of the distri-
bution of time to healing/recurrence and time to other 
events, that is, amputation and death will be assessed 
and alternative models considered if there are sufficient 
competing risks.
A multivariable Cox proportional hazards regression 
model will be fitted to explore risk factors predictive of 
time to healing.
Economic evaluation
A within- trial economic evaluation will be undertaken at 
week 52 post randomisation. The proposed secondary 
endpoints and methods for the economic evaluation 
follow the reference case set out by NICE.32 The primary 
economic analysis will be a cost- utility analysis presenting 
incremental cost- effectiveness ratios (ICERs) for each 
treatment strategy in rank order of effectiveness, with 
effects expressed in terms of quality- adjusted life years 
(QALYs). An NHS and Personal Social Services perspec-
tive for costs will be adopted. Costs and effects for each 
treatment strategy will be calculated for the trial follow- up 
period of 52 weeks.
Health resource use questionnaires will collect infor-
mation on NHS and personal social care use in line with 
NICE guidelines.32 This will include primary, secondary 
and community resource use. Unit cost data will be 
obtained from national databases such as the British 
National Formulary and Personal Social Services Research Unit 
Costs of Health and Social Care.
Treatment costs include the cost of delivering each 
strategy (mainly given by person- time of healthcare 
professionals) and the cost of the necessary equipment. 
The scope of resources considered includes the direct 
healthcare costs incurred for necessary patient care and 
excludes resources driven by the study protocol (eg, 
routine clinics will be included, while research visits that 
are just for checking for reulceration are excluded; also, 
the cost of photography and visit time for collecting data 
for study purposes will be excluded). To cost the treatment 
strategies, data on average duration of appointments for 
delivering the treatment strategy will be collected.
ICERs, incremental net monetary benefit and incre-
mental net health benefit statistics will be computed. 
NICE considers a cost per QALY within the range of £20 
000–£30 000 to be acceptable.32
Multiple imputation will be used to address any issues 
of missing data in the base case analysis on the assump-
tion of MAR. Complete case analysis will be conducted as 
a sensitivity analysis.
Probabilistic sensitivity analysis will be used to assess 
the impact of sampling uncertainty on the within- trial 
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evaluation results. Simulated cost and QALY estimates 
will be plotted on the cost- effectiveness plane to illustrate 
the uncertainty surrounding cost- effectiveness estimates33 
and presented as cost- effectiveness acceptability frontier 
to capture the varying probability of interventions being 
the most cost- effective over a range of willingness to pay 
for QALY thresholds.34
In addition, alternative scenarios will be explored in 
the sensitivity analysis to test the robustness of the main 
trial analysis results.
data management
Data will be monitored for quality and completeness and 
missing data will be chased up. Data received, including 
photographs will be stored in a secure database at Leeds 
CTRU in accordance with the 2018 Data Protection Act 
and the General Data Protection Regulation.
Patient and public involvement
The trial was supported at the stage of developing the 
grant application by the Sheffield Teaching Hospitals Lay 
Advisory Panel for Diabetes & Endocrinology Research. 
Their input was central to study design, actively helping 
to shape discussions and decisions through written feed-
back and group discussion. In particular they informed 
decisions on how frequently patients should be reassessed 
at the study site; whether patients would be willing to 
report healing or other outcomes directly to the research 
team or through their community clinician; agreement to 
completion of questionnaires; wound tracing and photo-
graphs which may be considered a burden; how willing 
patients will be to take part in the study; the acceptability 
of each intervention.
The trial has two Patient and Public Involvement 
(PPI) representatives on the Trial Steering Committee 
who have provided input into the patient information 
sheet and other trial documentation intended for use by 
patients. The PPI representatives also provide input into 
the design and conduct of the trial at 6 monthly meetings. 
This high- level involvement in project management aims 
to ensure patients’ perspectives are fully integrated in key 
decisions about the trial, delivery and interpretation/
dissemination of findings.
dIsCussIon
MAMs design
The chosen MAMS design provides an efficient plat-
form for assessment of several competing interventions, 
quickly homing in on the treatment strategy with greatest 
potential to be effective, early dropping of ineffective 
treatments and allowing assessment of combinations of 
treatments.20 35–37 Specific advantages of the MAMS design 
include comparing multiple treatment arms to a shared 
control group thereby requiring fewer patients, improved 
consent/recruitment rates since patients are more likely 
to receive an active treatment37 and common eligibility 
criteria across trial arms.20 Moreover, recruitment to all 
treatment strategies will continue during analysis and 
reporting of phase II data to ensure no loss of momentum 
in recruitment at sites.
Choice of endpoints
Reduction in ulcer area at 4 weeks was chosen as the 
primary outcome at phase II to be consistent with 
published observational studies38 39 and DFU RCTs.40 
This intermediate outcome measure provides a means of 
screening for ‘emerging evidence’ of efficacy, as it occurs 
earlier and more frequently than the definitive outcome 
measure and that it is on the causal pathway.41 Thus, it 
allows the phase II analysis and decision on treatment 
selection to take place in a timely manner.
Time to healing, the primary endpoint in phase III, was 
chosen as an important outcome measure from both clin-
ical and economic perspectives.30
Ulcer infection is the most common complication 
in non- healing ulcers, occurring in more than 50% of 
DFUs.6 It results in delayed healing, prolonged treat-
ment, increased resource use and increases the risk of 
a patient requiring a major amputation.42 IDSA criteria 
is recognised as a gold standard for characterisation of 
infection in DFUs in many national and international 
guidelines and will provide a reproducible system for clin-
ical diagnosis and severity stratification.12 21 43
No single patient- reported outcome measure has been 
identified as a ‘gold standard’ for assessing HRQoL in 
diabetes- related foot disease.11 As a result, both the disease- 
specific questionnaire, DFS- SF44 and the preference- based 
utility measure, EQ- 5D- 5L ( www. euroqol. org),45 will be 
completed by patients. The DFS- SF questionnaire has 
acceptable psychometric properties for measuring quality 
of life for patients with DFUs. The EQ- 5D is a generic 
instrument and forms part of the NICE reference case for 
cost per QALY analysis.
blinded assessment of healing
Having a blinded assessment of healing is important in 
reducing the risk of assessment bias and the trial includes 
independent, blinded clinical assessment of healing at 
both the first and confirmation of healing assessments, 
along with additional blinded review of photography 
undertaken by clinicians (Chief Investigator (vascular 
surgeon) and clinical nurse specialists).
revision to trial design
Since opening, the trial has undergone a trial redesign. 
The original design included a fourth treatment strategy 
in phase II corresponding to a combination of HD and 
NPWT as an adjunct to TAU, and also allowed a maximum 
of two treatment strategies to go forward into phase III 
under the same progression criteria. This original design 
required a maximum sample size of 660 participants, 324 
participants recruited in phase II and 336 in phase III, 
under the sample size assumptions. Following a review of 
treatment strategies which would be considered in clin-
ical practice if shown to be clinically effective and cost 
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effective, a revised trial design dropped the combination 
of the HD and NPWT arm, which reduced the maximum 
sample size to 447 patients while still ensuring a trial of 
clinical relevance.
hard-to-heal ulcers
A registration phase was also included in the original trial 
design. It is important that the trial includes a patient 
population with ‘hard- to- heal’ ulcers, reflecting the target 
population that would be considered for such adjuvant 
therapies in clinical practice. As there is variability in 
usual wound area assessment and documentation across 
recruiting centres, the registration phase included in 
the original design allowed a consistent approach to 
assessment of healing over a 4- week run- in period, and 
thereby considered ‘best practice’ for trials of DFU 
healing. However, the recently published LeucoPatch 
Trial,46 using an identical registration phase criterion of 
50% healing at 4 weeks, reported only 22% healing in 
the control and 34% healing in the intervention arms, 
suggesting that this registration phase criteria is overly 
selective in the definition of ‘hard- to- heal’. Early audit 
of data from a single centre in MIDFUT showed that 
patients were not recruited to the trial at presentation to 
an MDT DFU clinic, and had been subjected to an ‘in 
house assessment period’ prior to registration in the trial. 
Seventy- five per cent of those failing the trial registration 
period due to ulcer healing of >50% remained unhealed 
at 12 weeks, suggesting the trial was excluding a group 
of ulcers that were in fact ‘hard- to- heal’. The 2018 UK 
National Diabetic Foot Care Audit data of 21 000 ulcer 
episodes reports 49.3% remain unhealed at 12 weeks, 
with 27.3% unhealed 24 weeks and a further 2.9% recur-
ring. Thus under half of ulcers unhealed at 12 weeks will 
heal in the subsequent 12 weeks, supporting a second 
inclusion criterion of ulcers that remain unhealed at a 
12- week time point.9 A parallel entry route was therefore 
introduced to allow patients with ulcers of ≥12 weeks 
duration, that are considered hard to heal by the treating 
MDT team, to proceed directly to randomisation.
Following challenges in recruiting patients and the 
supporting evidence that a large proportion of patients 
with hard- to- heal ulcers were being missed, a decision 
was made to drop the registration phase for all patients. 
Instead, included ulcers will have failed to reduce in area 
by >50% over at least 4 weeks as measured using local 
measurement techniques. This allows a more pragmatic 
approach to be taken in identifying patients with hard- to- 
heal ulcers by using local wound measurement policies, 
thereby minimising the risk of missing potentially eligible 
patients while ensuring the trial results are more general-
isable to the target patient population.
Adjuvant therapies
It is not anticipated that there will be a rapid change 
in the technologies investigated in this trial, other than 
design changes aimed at increasing clinician and patient 
acceptance, again increasing the potential adoption and 
generalisability of the trial outcomes.
trial status
The first participant was registered on 10 August 2017 
and the first participant randomised on 30 October 
2017. As of 4 December 2019, 167 participants have been 
registered and 88 randomised. Recruitment is expected 
to complete by 31 August 2022. The full trial protocol is 
available on the National Institute for Health Research 
journals library https://www. journalslibrary. nihr. ac. uk/ 
programmes/ hta/ 150877/#/.
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